CDP Choline

Last week, I spent the week at PD Summer School, a full week of Parkinson’s wellness education. Dr. Laurie Mischley has spent the last 2 decades studying lifestyle and nutrition factors associated with either slower (better) or faster (worse) progression of Parkinson’s disease. The goal is to identify and implement positive deviance strategies that can be used to slow Parkinson’s disease progression ...

Trends in PD research are showing that in addition to Parkinson’s impact on the neurotransmitter dopamine and the dopamingeric system, the neurotransmitter acetylcholine and the brain’s cholingeric system are also impacted. This post reviews recent research (and some very old research that may need to be revisited), and discusses how two vitamins/supplements (Vitamin B12 and Citicoline/CDP Choline) may impact Parkinson’s disease. This should not be considered medical advice. Always consult your doctors and pharmacist about any vitamins or supplements that you are taking or considering. Related: Exhibit A: Yale Study challenges assumptions about PD and acetylcholine Several weeks ago, a ...

This Week's Highlights: Beer festival therapy; "How Parkinson’s gave me a better long-range jumper, a better baseball throwing arm, and a better outlook on life!"; impulse control disorders; PD and Vitamins B12 & D; into the rabbit hole of vitamins and supplements ...

This is a recap of the most interesting news and discussions relating to Parkinson’s Disease this past week. There was a lot of talk last week about the results of the Parkinson’s Disease trial in the UK involving a surgery that implanted tubes in patients’ heads that could be used post-surgery to deliver GDNF and would hopefully regenerate dying dopamine brain cells. On, the other side of the pond, the FDA is allowing a Fecal Microbiota Transplantation (yes, we’re talking about poop transplants) study to include Parkinson’s. Meanwhile in California, a stem cell PD trial moves closer to FDA approval. And ...

A study published this week raises an interesting point: Mobility deficits, including gait disturbance, balance impairments and falls, are common features of Parkinson's disease (PD) that negatively impact quality of life. Mobility deficits respond poorly to dopaminergic medications, indicating a role for additional neurotransmitters. Due to the critical role of cortical input to gait and balance, acetylcholine-an essential neurotransmitter system for attention-has become an area of interest for mobility. Overview of the cholinergic contribution to gait, balance and falls in Parkinson's disease I find this interesting, because the first Movement Disorder Specialist that I met with to confirm my Parknson’s ...